Ken Griffin Theseus Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$2.12 - $4.18 $93,487 - $184,329
44,098 New
44,098 $178,000
Q2 2023

Aug 14, 2023
BUY
$7.28 - $11.82 $874,793 - $1.42 Million
120,164 Added 24.81%
604,550 $5.64 Million
Q1 2023

May 15, 2023
BUY
$5.21 - $14.05 $2.52 Million - $6.81 Million
484,386 New
484,386 $4.3 Million

Others Institutions Holding THRX

# of Institutions
2
Shares Held
1.03M
Call Options Held
0
Put Options Held
0
View Full List

About Theseus Pharmaceuticals, Inc.

THRX Quotes by TradingView
  • Ticker THRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,713,400
  • Description
  • Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...
More about THRX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email